All three studied doses (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints
Its safety profile is similar to existing incretin-based therapies, making it a particularly promising candidate for obesity, type 2 diabetes, and related metabolic conditions
What labs should I check before and during treatment
The activation of GLP-1 tells your brain that you're full sooner, while GIP enhances sugar processing and insulin regulation
Ozempic and Wegovy Explained Semaglutide, the active ingredient in both Ozempic and Wegovy, has revolutionized the treatment of type 2 diabetes and obesity
The powerful, synergistic effect of CJC 1295 and Ipamorelin depends on the integrity of these molecules